Supplementary Materials
Identification of Novel Markers that Outperform EpCAM in Quantifying Circulating
Tumor Cells
Min-Ji Kim1, Na Young Choi2, Eun Kyung Lee1,3, Myung-Soo Kang1, 3,*
1
Samsung Biomedical Research Institute and Samsung Medical Center, Seoul, Korea 135-
718, 2Department of Nursing, Kyungdong University. 815 Kyonwhon-ro, Munmap-eup,
Gangwon-do 220-804, Korea. 3Department of Health Sciences and Technology, Samsung
Advanced Institute for Health Sciences and Technology, Samsung Biomedical Research
Institute and Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul,
Korea 135-718
Running Title: Novel Circulating Tumor Cell Markers
*
Corresponding author: Samsung Advanced Institute Health Sciences and Technology,
Samsung Medical Center, Sungkyunkwan University School of Medicine, 50 Irwon-dong,
Gangnam-gu, Seoul Korea 135-710 135-710. Tel:82-2-3410-1038, Fax: 82-2-3410-0534;
email: mkang@skku.edu
Fig. S1. Biostatistical analyses of CTC markers EpCAM, KRT19 and KRT7
Fig. S2. Analyses of additional pan-CTC markers SNX7, PTGR1, LAMB1, PRSS23 and
GNG12.
Fig. S3. Biostatistics analyses of EpCAM-/low markers assessed by boxplot (A), histogram (B)
and ROC (C) analyses.
Table S1. Sample information of 967 cancer cell lines used in the Cancer Cell Line
Encyclopedia microarray database
Table S2. Detail of 48 pan-CTC and 6 lymphocyte-depletion markers that are found as
uniformly over-expressed genes (OG) and under-expressed genes (UG), respectively, in AOC
over LL groups in Fig. 1, with greater statistical significance than EpCAM and PTPRC,
respectively.
Table S3. Genes that are over-expressed (pink background) and under-expressed (green
background) by more than 32-fold (log2FC > 5) in the specified group over LL. The boxed
genes denote the 12 best pan-CTC markers and 6 leukocyte depletion markers. Blue letters
denote markers unique to the specified type, a subset of which is cancer type-specific. Genes
are ranked from top to bottom in the order of the highest over-expression to the lowest underexpression.
Table S4. Detail of 136 genes shown in the heat map from Fig. 2. Gene list, expression mean
in the AOC and LL groups, mean difference (log2(Fold Change)) between specified groups of
cancer (AOC or 21 other tumor types) and LL (e.g. log2((FC_AOC) /FC_LL)) and p values
of the WRS test for mean distribution and Kolmogorov-Smirnov test for distribution of all the
data points (not shown) within the specified group compared to those of LL. *Values
transformed in log2 scale. #Markers classified by single test between AOC and LL or 21 tests
between each of the 21 groups and LL. PAN, pan-CTC marker; E-/low, markers for CTC
derived from Non/Low EpCAM cancer groups; Specific, makers for a specific cancer group.
Table S5. Validation of CTC markers from this study for a subset of universally overexpressed genes in diverse cancer tissues in an independent Bitter multi-cancer study.
Table S6. GO terms in gene ontology analyses using the 136 gene markers shown in Fig. 2
and Table S4.